Rare Disease Genetic Testing Support Programs

As genetic testing becomes more accessible, how are companies incorporating these technologies into their strategy?

Quick Takes

The Role of RWE in Supplemental or Conditional Approvals

RWE has become increasingly important in supporting supplemental or conditional drug approvals. Where is the space headed?

Quick Takes

Trump/HHS Proposal to Change Federal Drug Rebates

What are the implications of the DHHS' new plan to overhaul prescription drug rebates for federal beneficiaries?

Quick Takes

Solving for the Future: Building Strategy through Forecasting

Key guiding principles for effective forecasting, common pitfalls, and how to use a forecast to develop better strategy

White Papers

Developing a Go-To-Market Strategy for Your Lead Asset

Launching a new therapy is a complex endeavor. We will review the various activities key to a successful drug launch.

White Papers

Building Flexibility into Your R&D Strategy

How can flexibility in clinical development can be incorporated at various points along an asset’s life cycle

White Papers

BIO International Convention

Principal Sam Ulin will give a presentation on The Landscape of Innovation 2019: Drivers of Value for Innovators on June 3, 2018.


Aligning Access Investments to Today’s Payer Realities

Navigating new challenges of market access and reimbursement for new pharmaceuticals in today's market

White Papers

The Evolving Market Access Landscape for Orphan Drugs

Recent changes in the orphan drug market access landscape and implications for pharmaceutical developers

White Papers

Greater Value Creation with Digital Health

Distinct ways that medtech companies can incorporate digital health technologies into their portfolios

White Papers

Investing in Rare Disease Patient Advocacy Groups

Investing early in PAGs’ success is a sound strategic move that may increase a company’s chances of success by forming a collaboration that enhances patient access

White Papers

The Challenges of Gene Therapy

Building a well thought-out plan to establish evidence of safety and of clinical utility to establish trust in a new platform

White Papers

Opportunity Assessment Through the In-Licensor’s Lens

Technical and transactional assessments required to identify the right type of partnership for a biotech’s asset or platform and overall business needs

White Papers